Intervacc is trading at €0.06, up 17.67%, after reporting only three confirmed infections among horses completing primary vaccination following 100,000 doses sold in the EU and UK.
- In its November 3 announcement, the company said the findings showed nearly 100% protection.
- Redeye discussed the data on November 4; the Q3 report is scheduled for November 12.